StockData

Precigen vs Xencor

PGEN and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PGEN and XNCR compare

Xencor is the larger company, worth 1.7 times as much as Precigen ($2.6B against $1.5B).

Xencor scores higher on the StockData Score (5 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPGENXNCR
Size and price
Market cap$1.5B$2.6B
Share price$4.29$34.50
Change, 1 year−11.5%131%
Change, 5 years11.1%−2.7%
Beta (5Y)1.20−0.05
Employees20260
StockData Score
Total score25 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score23 (better)
Dividend score00
Valuation
P/S–24.4×
P/B35.2×5.1× (better)
FCF yield−7.5% (better)−8.1%
Fair value–$11.73
Margin of safety–−194%
Growth
Revenue growth (TTM)–−28.6%
Revenue growth, 5Y average−21.3%0.47% (better)
Profitability
Operating margin–−206%
Net margin–−156%
FCF margin–−198%
Return on equity−4640%−29.1% (better)
Return on invested capital–−26.6%
Financial health
Debt / equity2.150.21 (better)
Interest coverage–−8.0×
Current ratio4.586.39 (better)
Altman Z-score−11.145.01 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.2%113%
Held by insiders44.9%1.6%
Insider net buying, 12 months−$32.5M−$7.5M (better)
Superinvestors holding1–
Short interest, % of float22.8%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.